8.337

1.22% 0.127

Zenas Biopharma Inc (ZBIO)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$8.21

Offen:

$8.09

24-Stunden-Volumen:

75,232

Relative Volume:

0.28

Marktkapitalisierung:

$353.83M

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

EPS:

Netto-Cashflow:

1W Leistung:

+14.31%

1M Leistung:

+16.39%

6M Leistung:

+0.00%

1J Leistung:

+0.00%

1-Tages-Spanne:

$8.00

$8.6999

1-Wochen-Bereich:

$6.54

$8.6999

52-Wochen-Spanne:

$5.83

$26.25

Zenas Biopharma Inc Stock (ZBIO) Company Profile

Firmenname

Zenas Biopharma Inc

Sektor

Healthcare (1172)

Branche

Biotechnology (680)

Telefon

857-271-2954

Adresse

852 WINTER STREET, SUITE 250, WALTHAM

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ZBIO's Discussions on Twitter

Vergleichen Sie ZBIO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ZBIO Zenas Biopharma Inc	8.32	353.83M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	500.31	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	679.85	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	580.15	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	240.33	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	252.79	26.76B	3.32B	-860.46M	-1.04B	-8.32

Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-04	Eingeleitet	Wolfe Research	Outperform
2024-12-16	Eingeleitet	H.C. Wainwright	Buy
2024-11-05	Eingeleitet	Rodman & Renshaw	Buy
2024-10-08	Eingeleitet	Citigroup	Buy
2024-10-08	Eingeleitet	Guggenheim	Buy
2024-10-08	Eingeleitet	Jefferies	Buy
2024-10-08	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten

07:27 AM

Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth? - Yahoo Finance UK

07:27 AM

Mar 12, 2025

Zenas BioPharma’s Obexelimab: A Promising Therapy with a Buy Rating and $30 Price Target - TipRanks

Mar 12, 2025

Mar 11, 2025

Certain Common Stock of Zenas BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2025. - Marketscreener.com

Mar 11, 2025

Mar 03, 2025

Viridian Therapeutics, Inc.\DE SEC 10-K Report - TradingView

Mar 03, 2025

Feb 18, 2025

Zenas BioPharma Targets Key 2025 Milestones For Obexelimab In Autoimmune Diseases - BERNAMA

Feb 18, 2025

Feb 12, 2025

Director Makes Bold Move with Major Stock Purchase in Zenas BioPharma! - TipRanks

Feb 12, 2025

Zenas BioPharma director Xiao Ting purchases $77,600 in common stock By Investing.com - Investing.com Australia

Feb 12, 2025

Feb 11, 2025

Zenas BioPharma director Xiao Ting purchases $77,600 in common stock - Investing.com

Feb 11, 2025

Feb 06, 2025

ZENAS BIOPHARMA TARGETS KEY 2025 MILESTONES FOR OBEXELIMAB IN AUTOIMMUNE DISEASES - BERNAMA

Feb 06, 2025

ZENAS BIOPHARMA ANNOUNCES KEY 2024 ACCOMPLISHMENTS AND 2025 BUSINESS OBJECTIVES TO SUPPORT THE GLOBAL DEVELOPMENT AND COMMERCIALIZATION OF THERAPIES FOR AUTOIMMUNE DISEASES - BERNAMA

Feb 06, 2025

Feb 05, 2025

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives - Marketscreener.com

Feb 05, 2025

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases - Wahanariau

Feb 05, 2025

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 - GlobeNewswire

Feb 05, 2025

Biotech Powerhouse: Zenas BioPharma's $350M War Chest Fuels Triple Clinical Trial Assault on Autoimmune Diseases - StockTitan

Feb 05, 2025

Wolfe Research Initiates Coverage of Zenas BioPharma (ZBIO) with Outperform Recommendation - MSN

Feb 05, 2025

Feb 04, 2025

Zenas BioPharma initiated with an Outperform at Wolfe Research - MSN

Feb 04, 2025

Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target - Marketscreener.com

Feb 04, 2025

Feb 03, 2025

Zenas Biopharma To Present At Guggenheim SMID Cap Biotech Conference On Feb 5 - BERNAMA

Feb 03, 2025

Jan 31, 2025

ZENAS BIOPHARMA TO PRESENT AT THE GUGGENHEIM SMID CAP BIOTECH CONFERENCE - BERNAMA

Jan 31, 2025

Jan 28, 2025

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times

Jan 28, 2025

Zenas BioPharma Takes Center Stage: Key Revelations Expected at Major Biotech Summit - StockTitan

Jan 28, 2025

Jan 22, 2025

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

Jan 22, 2025

Jan 01, 2025

Biotech IPO Shares 2025 Climb In Trading Debuts After Deals Upsized - Browvopetshop

Jan 01, 2025

Dec 17, 2024

Zenas BioPharma initiated with a Buy at H.C. Wainwright - Yahoo Finance

Dec 17, 2024

Dec 16, 2024

HC Wainwright & Co. Initiates Coverage of Zenas BioPharma (ZBIO) with Buy Recommendation - MSN

Dec 16, 2024

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Dec 16, 2024

H.C. Wainwright starts Zenas stock with Buy rating, eyes Obexelimab’s role in autoimmune treatment - Investing.com Australia

Dec 16, 2024

Dec 13, 2024

Guggenheim maintains buy on ZBIO shares, sees strong drug potential By Investing.com - Investing.com Canada

Dec 13, 2024

Dec 12, 2024

Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley - Yahoo Finance

Dec 12, 2024

Dec 04, 2024

Zenas BioPharma CEO Leon O. Moulder Jr. purchases $718,100 in stock - Investing.com

Dec 04, 2024

Nov 21, 2024

Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth $148,925 By Investing.com - Investing.com South Africa

Nov 21, 2024

Nov 20, 2024

Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth $148,925 - Investing.com

Nov 20, 2024

Nov 14, 2024